



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 1661

PRINTER'S NO. 3026

PRIME SPONSOR: Metzgar

COST / (SAVINGS)

FUND	FY 2023/24	FY 2024/25
General Fund	See Fiscal Impact	See Fiscal Impact

SUMMARY:

Classifies xylazine as a Schedule III controlled substance and provides exceptions for veterinary use.

ANALYSIS:

House Bill 1664, Printer's Number 3026 amends Act 64 of 1972 (the Controlled Substance, Drug, Device and Cosmetic Act) to define xylazine and to classify it as a Schedule III controlled substance. The bill clarifies that xylazine is not a controlled substance when used for veterinary purposes and establishes requirements for the safe storage of xylazine by veterinarians.

This legislation would take effect immediately upon enactment.

FISCAL IMPACT:

The illicit use of xylazine is a felony with conviction punishable by imprisonment of up to five years or a fine of up to \$15,000, or both.

According to the Pennsylvania Sentencing Commission, data are not available to reliably estimate how many individuals may be convicted and sentenced. Therefore, their potential fiscal impact on the Commonwealth is indeterminable. It should be noted that the 2021/2022 marginal cost per day to incarcerate an individual in a State Correctional Institution was \$41.68.

Any revenue generated by fines in this section would be distributed to counties depending on the location of the penalty pursuant to 42 Pa.C.S. § 3572.

PREPARED BY: Bradley Keen
House Appropriations Committee (D)

DATE: May 6, 2024

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.